Combination of Heart-Type Fatty Acid Binding Protein and Brain Natriuretic Peptide Can Reliably Risk Stratify Patients Hospitalized for Chronic Heart Failure

• Niizeki Takeshi

  First Department of Internal Medicine, Yamagata University School of Medicine

• Takeishi Yasuchika

  First Department of Internal Medicine, Yamagata University School of Medicine

• Arimoto Takanori

  First Department of Internal Medicine, Yamagata University School of Medicine

• Takahashi Tatsuya

  Department of Diagnostic Information and Socioenvironmental Medicine, Yamagata University School of Medicine

• Okuyama Hidenobu

  First Department of Internal Medicine, Yamagata University School of Medicine

• Takabatake Noriaki

  First Department of Internal Medicine, Yamagata University School of Medicine

• Nozaki Naoki

  First Department of Internal Medicine, Yamagata University School of Medicine

• Hirono Osamu

  First Department of Internal Medicine, Yamagata University School of Medicine

• Tsunoda Yuichi

  First Department of Internal Medicine, Yamagata University School of Medicine

• Shishido Tetsuro

  First Department of Internal Medicine, Yamagata University School of Medicine

• Takahashi Hiroki

  First Department of Internal Medicine, Yamagata University School of Medicine

• Koyama Yo

  First Department of Internal Medicine, Yamagata University School of Medicine

• Fukao Akira

  Department of Diagnostic Information and Socioenvironmental Medicine, Yamagata University School of Medicine

• Kubota Isao

  First Department of Internal Medicine, Yamagata University School of Medicine

抄録

Background The aim of the present study was to prospectively study whether a combination of markers for myocardial cell injury and left ventricular overload at admission can reliably risk stratify patients hospitalized for chronic heart failure (CHF). Methods and Results Serum concentrations of heart-type fatty acid binding protein (H-FABP) and plasma concentrations of brain natriuretic peptide (BNP) were measured at admission in 186 consecutive patients hospitalized for CHF. During a mean follow-up period of 534±350 days, there were 44 cardiac events, including 16 cardiac deaths and 28 readmissions for worsening heart failure. Normal upper limits for H-FABP and BNP values were determined from the receiver operating characteristic curves (4.3 ng/ml for H-FABP and 200 pg/ml for BNP). A stepwise Cox regression analysis demonstrated that high H-FABP (hazard ratio 5.416, p=0.0002) and high BNP (hazard ratio 2.411, p=0.0463) were independent predictors of cardiac events. High concentrations of both H-FABP and BNP at admission were associated with the highest incidence of cardiac mortality and cardiac events. Kaplan-Meier analysis also showed that the combination of H-FABP and BNP concentrations could reliably stratify patients for cardiac events. Conclusion Combined measurement of H-FABP and BNP concentrations at admission may be a highly reliable evaluation for risk stratifying patients hospitalized for CHF. (Circ J 2005; 69: 922 - 927)<br>

収録刊行物

• Circulation Journal

  Circulation Journal 69 (8), 922-927, 2005

  一般社団法人 日本循環器学会

キーワード

• Brain natriuretic peptide (BNP)
• Heart failure
• Heart-type fatty acid binding protein (H-FABP)
• Prognosis

詳細情報

• CRID: 1390001205103034496
• NII論文ID: 110002696202
• NII書誌ID: AA11591968
• DOI: 10.1253/circj.69.922
• COI: 1:CAS:528:DC%2BD2MXpsVamtLo%3D
• ISSN: 13474820
• ISSN: 13469843
• PubMed: 16041160
• Web Site: https://www.jstage.jst.go.jp/article/circj/69/8/69_8_922/_pdf
• Web Site: https://search.jamas.or.jp/link/ui/2006279292
• 本文言語コード: en
• データソース種別:
  • JaLC
  • Crossref
  • PubMed
  • CiNii Articles
• 抄録ライセンスフラグ: 使用不可